Pre-made Nimacimab benchmark antibody ( Whole mAb, anti-CNR1/CB1 therapeutic antibody, Anti-CANN6/CB-R Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-376
Pre-Made Nimacimab biosimilar, Whole mAb, Anti-CNR1/CB1 Antibody: Anti-CANN6/CB-R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
A first-in-class, only-in-class peripheral antagonist antibody to cannabinoid receptor 1 (CB1) for the treatment of fibrotic, metabolic, and inflammatory diseases including nonalcoholic steatohepatitis (NASH) and diabetic kidney disease (DKD).
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Nimacimab biosimilar, Whole mAb, Anti-CNR1/CB1 Antibody: Anti-CANN6/CB-R therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Bird Rock Bio|
|Conditions Active||Diabetic nephropathies;Diabetic gastroparesis;Obesity|
|Conditions Discontinued||Non-alcoholic steatohepatitis;Non-alcoholic fatty liver disease|